
211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
The Readout Loud
00:00
Innovation Is Good for Wall Street
Gerry: Biote innovation has destroyed the market value of the companies involved. Like bluebird member, all the excitement five years ago, like theywere going to cure everything, it's like, go it's out of business. It's as far as many portfolio managers and other people at the investment banking level are concerned. Gerryd: We've got a lot of em analysts on the research team here that are going, and i feel like just giving what we've already seen out of the abstracts. And again, what i feel will be mainly smaller up dates on the spectrum.
Transcript
Play full episode